Laser photocoagulation for retinal vein occlusion
<p class="p1"><span class="s1">Retinal vein occlusion (RVO) is one of the leading causes of permanent vision loss. In adults, central retinal vein occlusion (CRVO) occurs in 1.8% while branch retinal vein occlusion (BRVO) occurs in 0.2%. Treatment strategy and disease...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ophthalmology Publishing Group
2015-03-01
|
| Series: | Oftalʹmologiâ |
| Subjects: | |
| Online Access: | http://www.ophthalmojournal.com/index.php/opht/article/view/222 |
| _version_ | 1819105748307673088 |
|---|---|
| author | K. A. Mirzabekova |
| author_facet | K. A. Mirzabekova |
| author_sort | K. A. Mirzabekova |
| collection | DOAJ |
| description | <p class="p1"><span class="s1">Retinal vein occlusion (RVO) is one of the leading causes of permanent vision loss. In adults, central retinal vein occlusion (CRVO) occurs in 1.8% while branch retinal vein occlusion (BRVO) occurs in 0.2%. Treatment strategy and disease prognosis are determined by RVO type (ischemic/non-ischemic). Despite numerous studies and many current CRVO and BRVO treatment approaches, the management of these patients is still being debated. Intravitreal injections of steroids (triamcinolone acetate, dexamethasone) and vascular endothelial growth factor (VEGF) inhibitors (bevacizumab, ranibizumab) were shown to be fairly effective. However, it is unclear whether anti-VEGF agents are reasonable in ischemic RVOs. Laser photocoagulation remains the only effective treatment of optic nerve head and/or retinal neovascularization. Laser photocoagulation is also indicated for the treatment of macular edema. Both threshold and sub-threshold photocoagulation may be performed. Photocoagulation performed with argon (514 nm), krypton (647 nm), or diode (810 nm) laser for macular edema provides similar results (no significant differences). The treatment may be complex and include medication therapy and/or surgery. Medication therapy includes anti-aggregant agents and antioxidants, i.e., emoxypine which may be used in acute RVO as well as in post-thrombotic retinopathy. </span></p> |
| first_indexed | 2024-12-22T02:27:10Z |
| format | Article |
| id | doaj.art-2633347bf42c46839272ba4bd44b11dd |
| institution | Directory Open Access Journal |
| issn | 1816-5095 |
| language | Russian |
| last_indexed | 2024-12-22T02:27:10Z |
| publishDate | 2015-03-01 |
| publisher | Ophthalmology Publishing Group |
| record_format | Article |
| series | Oftalʹmologiâ |
| spelling | doaj.art-2633347bf42c46839272ba4bd44b11dd2022-12-21T18:41:59ZrusOphthalmology Publishing GroupOftalʹmologiâ1816-50952015-03-011213338217Laser photocoagulation for retinal vein occlusionK. A. Mirzabekova0Research Institute of Eye Diseases, 11A, Rossolimo Str. Moscow, 119021, Russia<p class="p1"><span class="s1">Retinal vein occlusion (RVO) is one of the leading causes of permanent vision loss. In adults, central retinal vein occlusion (CRVO) occurs in 1.8% while branch retinal vein occlusion (BRVO) occurs in 0.2%. Treatment strategy and disease prognosis are determined by RVO type (ischemic/non-ischemic). Despite numerous studies and many current CRVO and BRVO treatment approaches, the management of these patients is still being debated. Intravitreal injections of steroids (triamcinolone acetate, dexamethasone) and vascular endothelial growth factor (VEGF) inhibitors (bevacizumab, ranibizumab) were shown to be fairly effective. However, it is unclear whether anti-VEGF agents are reasonable in ischemic RVOs. Laser photocoagulation remains the only effective treatment of optic nerve head and/or retinal neovascularization. Laser photocoagulation is also indicated for the treatment of macular edema. Both threshold and sub-threshold photocoagulation may be performed. Photocoagulation performed with argon (514 nm), krypton (647 nm), or diode (810 nm) laser for macular edema provides similar results (no significant differences). The treatment may be complex and include medication therapy and/or surgery. Medication therapy includes anti-aggregant agents and antioxidants, i.e., emoxypine which may be used in acute RVO as well as in post-thrombotic retinopathy. </span></p>http://www.ophthalmojournal.com/index.php/opht/article/view/222retinal vein occlusioncomplex treatmentlaser photocoagulation |
| spellingShingle | K. A. Mirzabekova Laser photocoagulation for retinal vein occlusion Oftalʹmologiâ retinal vein occlusion complex treatment laser photocoagulation |
| title | Laser photocoagulation for retinal vein occlusion |
| title_full | Laser photocoagulation for retinal vein occlusion |
| title_fullStr | Laser photocoagulation for retinal vein occlusion |
| title_full_unstemmed | Laser photocoagulation for retinal vein occlusion |
| title_short | Laser photocoagulation for retinal vein occlusion |
| title_sort | laser photocoagulation for retinal vein occlusion |
| topic | retinal vein occlusion complex treatment laser photocoagulation |
| url | http://www.ophthalmojournal.com/index.php/opht/article/view/222 |
| work_keys_str_mv | AT kamirzabekova laserphotocoagulationforretinalveinocclusion |